G-CSF and Exenatide Might Be Associated with Increased Long-Term Survival of Allogeneic Pancreatic Islet Grafts

Alessia Zoso, Paolo Serafini, Giacomo Lanzoni, Eduardo Peixoto, Shari Messinger, Alejandro Mantero, Nathalia D. Padilla-Téllez, David Baidal, Rodolfo Alejandro, Camillo Ricordi, Luca A Inverardi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

BACKGROUND: Allogeneic human islet transplantation is an effective therapy for the treatment of patients with Type 1 Diabetes (T1D). The low number of islet transplants performed worldwide and the different transplantation protocols used limit the identification of the most effective therapeutic options to improve the efficacy of this approach.

METHODS: We present a retrospective analysis on the data collected from 44 patients with T1D who underwent islet transplantation at our institute between 2000 and 2007. Several variables were included: recipient demographics and immunological characteristics, donor and transplant characteristics, induction protocols, and additional medical treatment received. Immunosuppression was induced with anti-CD25 (Daclizumab), alone or in association with anti-tumor necrosis factor alpha (TNF-α) treatments (Etanercept or Infliximab), or with anti-CD52 (Alemtuzumab) in association with anti-TNF-α treatments (Etanercept or Infliximab). Subsets of patients were treated with Filgrastim for moderate/severe neutropenia and/or Exenatide for post prandial hyperglycemia.

RESULTS: The analysis performed indicates a negative association between graft survival (c-peptide level ≥ 0.3 ng/ml) and islet infusion volume, with the caveat that, the progressive reduction of infusion volumes over the years has been paralleled by improved immunosuppressive protocols. A positive association is instead suggested between graft survival and administration of Exenatide and Filgrastim, alone or in combination.

CONCLUSION: This retrospective analysis may be of assistance to further improve long-term outcomes of protocols for transplant of islets and other organs.

Original languageEnglish (US)
Pages (from-to)e0157245
JournalPLoS One
Volume11
Issue number6
DOIs
StatePublished - 2016

Fingerprint

islets of Langerhans
Granulocyte Colony-Stimulating Factor
Islets of Langerhans
Grafts
Transplants
insulin-dependent diabetes mellitus
Association reactions
Transplantation (surgical)
c-peptide
Medical problems
immunosuppressive agents
Islets of Langerhans Transplantation
neutropenia
therapeutics
medical treatment
immunosuppression
Graft Survival
hyperglycemia
Type 1 Diabetes Mellitus
tumor necrosis factor-alpha

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

G-CSF and Exenatide Might Be Associated with Increased Long-Term Survival of Allogeneic Pancreatic Islet Grafts. / Zoso, Alessia; Serafini, Paolo; Lanzoni, Giacomo; Peixoto, Eduardo; Messinger, Shari; Mantero, Alejandro; Padilla-Téllez, Nathalia D.; Baidal, David; Alejandro, Rodolfo; Ricordi, Camillo; Inverardi, Luca A.

In: PLoS One, Vol. 11, No. 6, 2016, p. e0157245.

Research output: Contribution to journalArticle

Zoso, Alessia ; Serafini, Paolo ; Lanzoni, Giacomo ; Peixoto, Eduardo ; Messinger, Shari ; Mantero, Alejandro ; Padilla-Téllez, Nathalia D. ; Baidal, David ; Alejandro, Rodolfo ; Ricordi, Camillo ; Inverardi, Luca A. / G-CSF and Exenatide Might Be Associated with Increased Long-Term Survival of Allogeneic Pancreatic Islet Grafts. In: PLoS One. 2016 ; Vol. 11, No. 6. pp. e0157245.
@article{fe8f4ded260f48bca1fd5d0e8108cdd3,
title = "G-CSF and Exenatide Might Be Associated with Increased Long-Term Survival of Allogeneic Pancreatic Islet Grafts",
abstract = "BACKGROUND: Allogeneic human islet transplantation is an effective therapy for the treatment of patients with Type 1 Diabetes (T1D). The low number of islet transplants performed worldwide and the different transplantation protocols used limit the identification of the most effective therapeutic options to improve the efficacy of this approach.METHODS: We present a retrospective analysis on the data collected from 44 patients with T1D who underwent islet transplantation at our institute between 2000 and 2007. Several variables were included: recipient demographics and immunological characteristics, donor and transplant characteristics, induction protocols, and additional medical treatment received. Immunosuppression was induced with anti-CD25 (Daclizumab), alone or in association with anti-tumor necrosis factor alpha (TNF-α) treatments (Etanercept or Infliximab), or with anti-CD52 (Alemtuzumab) in association with anti-TNF-α treatments (Etanercept or Infliximab). Subsets of patients were treated with Filgrastim for moderate/severe neutropenia and/or Exenatide for post prandial hyperglycemia.RESULTS: The analysis performed indicates a negative association between graft survival (c-peptide level ≥ 0.3 ng/ml) and islet infusion volume, with the caveat that, the progressive reduction of infusion volumes over the years has been paralleled by improved immunosuppressive protocols. A positive association is instead suggested between graft survival and administration of Exenatide and Filgrastim, alone or in combination.CONCLUSION: This retrospective analysis may be of assistance to further improve long-term outcomes of protocols for transplant of islets and other organs.",
author = "Alessia Zoso and Paolo Serafini and Giacomo Lanzoni and Eduardo Peixoto and Shari Messinger and Alejandro Mantero and Padilla-T{\'e}llez, {Nathalia D.} and David Baidal and Rodolfo Alejandro and Camillo Ricordi and Inverardi, {Luca A}",
year = "2016",
doi = "10.1371/journal.pone.0157245",
language = "English (US)",
volume = "11",
pages = "e0157245",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

TY - JOUR

T1 - G-CSF and Exenatide Might Be Associated with Increased Long-Term Survival of Allogeneic Pancreatic Islet Grafts

AU - Zoso, Alessia

AU - Serafini, Paolo

AU - Lanzoni, Giacomo

AU - Peixoto, Eduardo

AU - Messinger, Shari

AU - Mantero, Alejandro

AU - Padilla-Téllez, Nathalia D.

AU - Baidal, David

AU - Alejandro, Rodolfo

AU - Ricordi, Camillo

AU - Inverardi, Luca A

PY - 2016

Y1 - 2016

N2 - BACKGROUND: Allogeneic human islet transplantation is an effective therapy for the treatment of patients with Type 1 Diabetes (T1D). The low number of islet transplants performed worldwide and the different transplantation protocols used limit the identification of the most effective therapeutic options to improve the efficacy of this approach.METHODS: We present a retrospective analysis on the data collected from 44 patients with T1D who underwent islet transplantation at our institute between 2000 and 2007. Several variables were included: recipient demographics and immunological characteristics, donor and transplant characteristics, induction protocols, and additional medical treatment received. Immunosuppression was induced with anti-CD25 (Daclizumab), alone or in association with anti-tumor necrosis factor alpha (TNF-α) treatments (Etanercept or Infliximab), or with anti-CD52 (Alemtuzumab) in association with anti-TNF-α treatments (Etanercept or Infliximab). Subsets of patients were treated with Filgrastim for moderate/severe neutropenia and/or Exenatide for post prandial hyperglycemia.RESULTS: The analysis performed indicates a negative association between graft survival (c-peptide level ≥ 0.3 ng/ml) and islet infusion volume, with the caveat that, the progressive reduction of infusion volumes over the years has been paralleled by improved immunosuppressive protocols. A positive association is instead suggested between graft survival and administration of Exenatide and Filgrastim, alone or in combination.CONCLUSION: This retrospective analysis may be of assistance to further improve long-term outcomes of protocols for transplant of islets and other organs.

AB - BACKGROUND: Allogeneic human islet transplantation is an effective therapy for the treatment of patients with Type 1 Diabetes (T1D). The low number of islet transplants performed worldwide and the different transplantation protocols used limit the identification of the most effective therapeutic options to improve the efficacy of this approach.METHODS: We present a retrospective analysis on the data collected from 44 patients with T1D who underwent islet transplantation at our institute between 2000 and 2007. Several variables were included: recipient demographics and immunological characteristics, donor and transplant characteristics, induction protocols, and additional medical treatment received. Immunosuppression was induced with anti-CD25 (Daclizumab), alone or in association with anti-tumor necrosis factor alpha (TNF-α) treatments (Etanercept or Infliximab), or with anti-CD52 (Alemtuzumab) in association with anti-TNF-α treatments (Etanercept or Infliximab). Subsets of patients were treated with Filgrastim for moderate/severe neutropenia and/or Exenatide for post prandial hyperglycemia.RESULTS: The analysis performed indicates a negative association between graft survival (c-peptide level ≥ 0.3 ng/ml) and islet infusion volume, with the caveat that, the progressive reduction of infusion volumes over the years has been paralleled by improved immunosuppressive protocols. A positive association is instead suggested between graft survival and administration of Exenatide and Filgrastim, alone or in combination.CONCLUSION: This retrospective analysis may be of assistance to further improve long-term outcomes of protocols for transplant of islets and other organs.

UR - http://www.scopus.com/inward/record.url?scp=85018870651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018870651&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0157245

DO - 10.1371/journal.pone.0157245

M3 - Article

C2 - 27285580

AN - SCOPUS:85018870651

VL - 11

SP - e0157245

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 6

ER -